NICE approves pemigatinib for those with CCA and the FGFR2 fusion

‚ÄúToday, 22 July 2021, the availability of pemigatinib marks a major milestone in the fight against cholangiocarcinoma, bringing new hope for our patients with this devastating type of liver cancer who have an FGFR2 genetic rearrangement. This advance, which requires our patients to have molecular testing, opens the door to gaining a much better understanding … Continue reading NICE approves pemigatinib for those with CCA and the FGFR2 fusion